Finding 1156308 (2024-003)

Material Weakness Repeat Finding
Requirement
C
Questioned Costs
-
Year
2024
Accepted
2025-09-29
Audit: 368577

AI Summary

  • Core Issue: Subrecipient payments were not made within the required 30-day timeframe as mandated by federal guidelines.
  • Impacted Requirements: This finding violates Section 200.303 of the Uniform Guidance regarding internal controls and 2 CFR 200.305(c) on timely payments.
  • Recommended Follow-Up: Management should prioritize improving processes to ensure compliance with the 30-day payment requirement for subrecipients.

Finding Text

Finding 2024-003 – Subrecipient Cash ManagementIdentification of the federal program:Federal Grantor: Department of Health and Human Services (HHS)Assistance Listing No.: 12.420, Military Medical Research and DevelopmentGrant Award: W81XWH2010210Federal Grantor: Department of Health and Human Services (HHS)Assistance Listing No.: 93.395, Cancer Treatment ResearchGrant Award: R01CA248574Federal Grantor: Department of Health and Human Services (HHS)Assistance Listing No.: 93.847, Diabetes, Digestive, and Kidney Diseases Extramural ResearchGrant Award: R01DK133328Criteria or specific requirement (including statutory, regulatory or other citation):Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”2 CFR 200.305 (c) states, “…the Federal agency or pass-through entity must make payment within 30 calendar days after receipt of the payment request unless the Federal agency or pass-through entity reasonably believes the request to be improper.”Condition:Management did not have sufficiently designed internal controls to ensure all payments made to subrecipients were made within the required time frames.Cause:Management did not ensure that all subrecipient cash payments were made within the required time frame.Effect or potential effect:Subrecipients are not paid within the time frame established in the Uniform Guidance.Questioned costs:None.Context:We tested a sample of 10 subrecipient payments, and identified 4 payments that were not paid within 30 days of receipt. Total expenditures for the Research and Development Cluster were $13,427,764 at December 31, 2024. Total subrecipient expenditures for the year ended December 31, 2024, were $2,133,172.Identification as a repeat finding, if applicable:This finding is not a repeat finding from the prior year.Recommendation:Management should ensure subrecipient payments are made within the required time frames included in the Uniform Guidance.Views of responsible officials:Management concurs with the finding and will increase the priority around the 30-day processing deadline mandated by the Uniform Guidance 2 FR 200.305 (b)(3), including review of current processes, policies, and procedures to minimize the time between invoice receipt and the transfer of federal funds to the subrecipient.

Corrective Action Plan

Finding 2024-003 – Subrecipient Cash ManagementAssistance Listing No.: MultipleThe Office of Sponsored Programs ( OSP) will address the recommendation and review its current processes, policies, and procedures to minimize the time between invoice receipt and the transfer of federal funds to the subrecipient. This includes implementation of the following preventative controls to ensure that payments are made within the required timeline: a. Active communications with Principal Investigators of subawards on invoice approval timeline at award initiation and creation of procedures for documenting and advising OSP of invoices requiring correction and /or modification. b. Work with Post Award Staff to ensure that adequate documentation is created and maintained related to the follow-up that occurs when issues are being investigated and resolved that cause a delay in invoice processing.c. Development and utilization of a report for internal reporting and tracking of pending sub-invoices payments approaching the 30-day deadline. d. Implementation of the Invoice Receipt Date as a required field for subaward invoicing in Workday rather than the optional field it is at present. Responsible Official: Cate Ekstrom, Director of Research

Categories

Subrecipient Monitoring Cash Management

Other Findings in this Audit

  • 1156219 2024-003
    Material Weakness Repeat
  • 1156220 2024-003
    Material Weakness Repeat
  • 1156221 2024-003
    Material Weakness Repeat
  • 1156222 2024-003
    Material Weakness Repeat
  • 1156223 2024-003
    Material Weakness Repeat
  • 1156224 2024-003
    Material Weakness Repeat
  • 1156225 2024-003
    Material Weakness Repeat
  • 1156226 2024-003
    Material Weakness Repeat
  • 1156227 2024-003
    Material Weakness Repeat
  • 1156228 2024-003
    Material Weakness Repeat
  • 1156229 2024-003
    Material Weakness Repeat
  • 1156230 2024-003
    Material Weakness Repeat
  • 1156231 2024-003
    Material Weakness Repeat
  • 1156232 2024-003
    Material Weakness Repeat
  • 1156233 2024-003
    Material Weakness Repeat
  • 1156234 2024-001
    Material Weakness Repeat
  • 1156235 2024-002
    Material Weakness Repeat
  • 1156236 2024-003
    Material Weakness Repeat
  • 1156237 2024-003
    Material Weakness Repeat
  • 1156238 2024-003
    Material Weakness Repeat
  • 1156239 2024-003
    Material Weakness Repeat
  • 1156240 2024-003
    Material Weakness Repeat
  • 1156241 2024-003
    Material Weakness Repeat
  • 1156242 2024-003
    Material Weakness Repeat
  • 1156243 2024-001
    Material Weakness Repeat
  • 1156244 2024-003
    Material Weakness Repeat
  • 1156245 2024-003
    Material Weakness Repeat
  • 1156246 2024-003
    Material Weakness Repeat
  • 1156247 2024-003
    Material Weakness Repeat
  • 1156248 2024-003
    Material Weakness Repeat
  • 1156249 2024-003
    Material Weakness Repeat
  • 1156250 2024-003
    Material Weakness Repeat
  • 1156251 2024-003
    Material Weakness Repeat
  • 1156252 2024-003
    Material Weakness Repeat
  • 1156253 2024-003
    Material Weakness Repeat
  • 1156254 2024-003
    Material Weakness Repeat
  • 1156255 2024-003
    Material Weakness Repeat
  • 1156256 2024-003
    Material Weakness Repeat
  • 1156257 2024-003
    Material Weakness Repeat
  • 1156258 2024-003
    Material Weakness Repeat
  • 1156259 2024-003
    Material Weakness Repeat
  • 1156260 2024-003
    Material Weakness Repeat
  • 1156261 2024-003
    Material Weakness Repeat
  • 1156262 2024-003
    Material Weakness Repeat
  • 1156263 2024-003
    Material Weakness Repeat
  • 1156264 2024-003
    Material Weakness Repeat
  • 1156265 2024-003
    Material Weakness Repeat
  • 1156266 2024-003
    Material Weakness Repeat
  • 1156267 2024-003
    Material Weakness Repeat
  • 1156268 2024-003
    Material Weakness Repeat
  • 1156269 2024-003
    Material Weakness Repeat
  • 1156270 2024-003
    Material Weakness Repeat
  • 1156271 2024-003
    Material Weakness Repeat
  • 1156272 2024-003
    Material Weakness Repeat
  • 1156273 2024-003
    Material Weakness Repeat
  • 1156274 2024-003
    Material Weakness Repeat
  • 1156275 2024-003
    Material Weakness Repeat
  • 1156276 2024-003
    Material Weakness Repeat
  • 1156277 2024-003
    Material Weakness Repeat
  • 1156278 2024-003
    Material Weakness Repeat
  • 1156279 2024-003
    Material Weakness Repeat
  • 1156280 2024-003
    Material Weakness Repeat
  • 1156281 2024-003
    Material Weakness Repeat
  • 1156282 2024-003
    Material Weakness Repeat
  • 1156283 2024-003
    Material Weakness Repeat
  • 1156284 2024-003
    Material Weakness Repeat
  • 1156285 2024-003
    Material Weakness Repeat
  • 1156286 2024-003
    Material Weakness Repeat
  • 1156287 2024-003
    Material Weakness Repeat
  • 1156288 2024-003
    Material Weakness Repeat
  • 1156289 2024-003
    Material Weakness Repeat
  • 1156290 2024-003
    Material Weakness Repeat
  • 1156291 2024-003
    Material Weakness Repeat
  • 1156292 2024-003
    Material Weakness Repeat
  • 1156293 2024-003
    Material Weakness Repeat
  • 1156294 2024-003
    Material Weakness Repeat
  • 1156295 2024-003
    Material Weakness Repeat
  • 1156296 2024-003
    Material Weakness Repeat
  • 1156297 2024-003
    Material Weakness Repeat
  • 1156298 2024-003
    Material Weakness Repeat
  • 1156299 2024-003
    Material Weakness Repeat
  • 1156300 2024-003
    Material Weakness Repeat
  • 1156301 2024-003
    Material Weakness Repeat
  • 1156302 2024-003
    Material Weakness Repeat
  • 1156303 2024-003
    Material Weakness Repeat
  • 1156304 2024-003
    Material Weakness Repeat
  • 1156305 2024-003
    Material Weakness Repeat
  • 1156306 2024-003
    Material Weakness Repeat
  • 1156307 2024-003
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.866 Aging Research $1.16M
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $1.07M
93.242 Mental Health Research Grants $775,500
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $582,530
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt)health Department Response to Public Health Or Healthcare Crisis $525,406
93.350 National Center for Advancing Translational Sciences $448,957
93.368 21st Century Cures Act - Precision Medicine Initiative $303,736
93.172 Human Genome Research $286,291
93.838 Lung Diseases Research $198,571
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $180,535
93.351 Research Infrastrcuture Programs $157,600
93.837 Cardiovascular Disease Research $108,016
93.994 Maternal and Child Health Services Block Grant to the States $100,083
93.268 Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects $92,586
93.859 Biomedical Research and Research Training $89,868
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $66,500
93.671 Family Violence Prevention and Services/domestic Violence Shelter and Supportive Seevices $66,397
93.865 Child Health and Human Development Extramural Research $61,357
14.218 Community Development Block Grants/entitlement Grants $34,846
93.395 Cancer Treatment Research $31,725
93.399 Cancer Control $26,068
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $24,024
93.226 Research on Healthcare Costs, Quality and Outcomes $22,635
93.855 Allergy, Immunology and Transplantation Research $19,234
12.420 Military Medical Research and Development $17,771
93.396 Cancer Biology Research $17,301
93.110 Maternal and Child Health Federal Consolidated Programs $16,507
93.353 Cancer Treatment Research $16,200
93.307 Minority Health and Health Disparities Research $12,526
93.397 Cancer Center Support Grants $10,797
93.889 National Bioterrorism Hospital Preparedness Program $10,000
93.839 Blood Diseases and Resources Research $7,626
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $7,192
93.935 Project Grants for Renovation Or Construction at Tertiary Perinatal Facilities $5,000
93.361 Nursing Research $4,563
93.667 Social Services Block Grant $2,346
93.394 Cancer Detetction and Diagnosis Research $356
93.310 Trans-Nih Research Support $-10,837